摘要
目的观察国产奈达铂（NDP）联合多西他赛二线治疗非小细胞肺癌的疗效和毒副反应。方法对57例ⅢB期和Ⅳ期非小细胞肺癌，应用奈达铂80mg／m^2-100mg／m^2，d1，多西他赛75mg／m^2，d1，21d为1个周期，至少接受2个周期化疗。结果57例患者均可评价疗效，其中，CR4例，PR16例，NC24例，PC13例，客观有效率（CR＋PR）35．1％，疾病控制率（CR＋PR＋SD）77．2％；中位疾病进展时间（TTP）为4．3个月，中位生存期为7．4个月，1年生存率为34．2％。本组血液学不良反应发生率较高，非血液学毒性方面恶心、呕吐，总发生率较高。结论国产奈达铂联合多西他赛二线治疗非小细胞肺癌是一种有效的方法，毒性反应轻，病人耐受良好。
Objective To investigate the therapeutic effect, long term survival and toxicities for advanced NSCLC patients treated with domestic nadaplatin combined with docetaxel. Methods 57 patients with histologically and/or cytologically confirmed advanced NSCLC were treated with domestic nadaplatin 80 - 100 mg/m^2 and docetaxel 75 mg/m^2 on dl, repeated every 3 weeks. Results The response rate of all the patients were evaluated. There were 4CR,16 PR,24 SD and 13 PD in the group,CR add PR was 35.1% ,CR add PR and SD was 77.2%. Median time to progression（TIP）was 4. 3 months. Median survival duration was 7.4 months. One year survival rate was 34.2%. There was high response in hematological toxicity, non - hematological toxicity were gastrointestinal reactions. Conclusions Domestic nadaplatin combined with docetaxel in second - line treatment for advanced non - small - cell lung cancer is effective, and toxicity is tolerated.
出处
《实用肿瘤学杂志》
CAS
2009年第5期456-458,482,共4页
Practical Oncology Journal
关键词
奈达铂
多西他赛
二线治疗
非小细胞肺癌
Nadaplatin
Docetaxel
Second - line treatment
Non - small - cell lung cancer
